MICHAEL MOYLAN: Open Payments
NPI 1407319163 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,844 in 71 payments from 18 companies in 2025. Trend: 2023 $1,192 · 2024 $819 · 2025 $1,844
Food & beverage: $1,724Education: $120
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $360 |
| Janssen Biotech, Inc. | 7 | $233 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $195 |
| Gilead Sciences, Inc. | 7 | $188 |
| Ardelyx, Inc. | 7 | $155 |
| Phathom Pharmaceuticals, Inc. | 6 | $144 |
| Madrigal Pharmaceuticals | 3 | $109 |
| Aimmune Therapeutics, Inc. | 4 | $91 |
| ABBVIE INC. | 5 | $90 |
| Lilly USA, LLC | 2 | $55 |
Products named: ENTYVIO, TREMFYA, XIFAXAN, IBSRELA, VOQUEZNA, GATTEX, REZDIFFRA, OMVOH.
Industry payments across RI — which companies pay providers there.
